Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer

European Journal of Health Economics

Volumn 16, Issue 6, 2015, Pages 657-670

  Mühlbacher, Axel C ^a,b   Bethge, Susanne ^a  

^a Hochschule Neubrandenburg   (Germany)

^b GEB MbH   (Germany)

Author keywords

Discrete choice experiment; Non small cell lung cancer; Patient preferences; Patient relevant treatment attributes

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPUTER AIDED DESIGN; COUGHING; DIARRHEA; DISCRETE CHOICE EXPERIMENT; DISEASE COURSE; DRUG ERUPTION; DYSPNEA; EMPIRICAL RESEARCH; EMPIRICISM; EXPERIMENT; FATIGUE; FEMALE; HUMAN; INTERVIEW; LUNG SURGERY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOTIVATION; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; OUTCOME ASSESSMENT; PATIENT DECISION MAKING; PATIENT PREFERENCE; PERSONAL INTERVIEW; POSTOPERATIVE NAUSEA; POSTOPERATIVE VOMITING; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITATIVE RESEARCH; RADIATION INDUCED EMESIS; RADIATION SICKNESS; RASH; VOCATIONAL EDUCATION; CARCINOMA, NON-SMALL-CELL LUNG; DECISION MAKING; DISEASE FREE SURVIVAL; LUNG NEOPLASMS; PSYCHOLOGY; SOCIOECONOMICS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHOICE BEHAVIOR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INTERVIEWS AS TOPIC; LUNG NEOPLASMS; MALE; MIDDLE AGED; PATIENT PREFERENCE; SOCIOECONOMIC FACTORS;

EID: 84930807180     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-014-0622-4     Document Type: Article

References (51)

1. Klemperer, D., Rosenwirth, M.: Shared decision making: Konzept, Voraussetzungen und politische Implikationen. In: Gütersloh (2005)
2. Bauer, H.: Zwischen Anspruch und Wirklichkeit: Etablierung der Evidenz-basierten Medizin (EbM) im chirurgischen Alltag. In: Rebscher, H. (ed.) Gesundheitsökonomie und Gesundheitspolitik im Spannungsfeld zwischen Wissenschaft und Politikberatung, Economica Verlag, Heidelberg pp. 505–525. Economica Verlagsgruppe, Heidelberg (2006)
3. Hummel, M.J.M., Snoek, G.J., Til, J.A., Rossum, W., Ijzerman, M.J.: A multicriteria decision analysis of augmentative treatment of upper limbs in persons with tetraplegia. J Rehabil Res Dev 42(5), 635–644 (2005)
4. Mühlbacher, A.C., Bethge, S., Ekert, S., Tockhorn, A., Nübling, M.: Der Wert von Innovationen im Gesundheitswesen: spielen die Patientenpräferenzen eine Rolle? Recht und Politik im Gesundheitswesen 14(2), 53–62 (2008)
5. Farin-Glattacker, E., Meder, M., Nagl, M.: Patientenorientierte Veränderungsmessung: Gesundheitsbewertungen und die Beurteilung der Teilhabe-Relevanz von Behandlungseffekten durch chronisch Kranke. Abschlussbericht zum Projekt In, Freiburg (2011)
6. Frosch, D.L., Härter, M., Simon, D., Mulley, A.G.: Variation und Verteilungsgerechtigkeit: patientenpräferenzen berücksichtigen. Deutsches Ärzteblatt 107(43), 2100–2104 (2010)
7. Institut für Qualität und Wirtschaftlicheit im Gesundheitswesen: Allgemeinen Methoden Version 4.1: Aktualisierung einiger Abschnitte der Allgemeinen Methoden Version 4.0 sowie neue Abschnitte zur Erstellung. In: Köln (2013)
8. Mühlbacher, A.C.: Patientenpräferenzen bei der Kosten-Nutzen-Bewertung. Interview. Patientenbrief. Ihr gesundheitspolitischer Fakten- & News-Letter (2008)
9. Mühlbacher, A.C., Bethge, S., Tockhorn, A.: Präferenzmessung im Gesundheitswesen: grundlagen von Discrete-Choice-Experimenten. Gesundheitsökonomie Qualitätsmanagement 18(4), 159–172 (2013)
10. Goeckenjan, G., Sitter, H., Thomas, M., Branscheid, D., Flentje, M., Griesinger, F., Niederle, N., Stuschke, M., Blum, T., Deppermann, K.-M.: Prävention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms. Pneumologie 64(S 02), e1–e164 (2010)
11. World Health Organization: Cancer. http://www.who.int/mediacentre/factsheets/fs297/en (2012)
12. Destatis: Gesundheit. Ergebnisse der Todesursachenstatistik für Deutschland. Ausführliche 4-stellige ICD-10 Klassifikation. Destatis. https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Todesursachen/Todesursachenstatistik.html;jsessionid=5C2A814B8DC87AC98C1C3A89CDD43400.cae4 (2012)
13. Peters, S., Adjei, A.A., Gridelli, C., Reck, M., Kerr, K., Felip, E., Group, o.b.o.t.E.G.W.: Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 23(suppl 7), vii56–vii64 (2012). doi:10.1093/annonc/mds226
14. Simonato, L., Agudo, A., Ahrens, W., Benhamou, E., Benhamou, S., Boffetta, P., Brennan, P., Darby, S.C., Forastiere, F., Fortes, C.: Lung cancer and cigarette smoking in Europe: an update of risk estimates and an assessment of inter-country heterogeneity. Int J Cancer 91(6), 876–887 (2001)
15. Wakelee, H.A., Chang, E.T., Gomez, S.L., Keegan, T.H., Feskanich, D., Clarke, C.A., Holmberg, L., Yong, L.C., Kolonel, L.N., Gould, M.K.: Lung cancer incidence in never smokers. J Clin Oncol 25(5), 472–478 (2007)
16. Ahrendt, S.A., Decker, P.A., Alawi, E.A., Zhu, Yr, Sanchez-Cespedes, M., Yang, S.C., Haasler, G.B., Kajdacsy-Balla, A., Demeure, M.J., Sidransky, D.: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92(6), 1525–1530 (2001)
17. Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L.: EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101(36), 13306–13311 (2004)
18. Jänne, P.A., Johnson, B.E.: Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 12(14), 4416s–4420s (2006). doi:10.1158/1078-0432.ccr-06-0555
19. Ettinger, D.S., Akerley, W., Bepler, G., Blum, M.G., Chang, A., Cheney, R.T., Chirieac, L.R., D’Amico, T.A., Demmy, T.L., Ganti, A.K., Govindan, R., Grannis, F.W., Jr., Jahan, T., Jahanzeb, M., Johnson, D.H., Kessinger, A., Komaki, R., Kong, F.M., Kris, M.G., Krug, L.M., Le, Q.T., Lennes, I.T., Martins, R., O’Malley, J., Osarogiagbon, R.U., Otterson, G.A., Patel, J.D., Pisters, K.M., Reckamp, K., Riely, G.J., Rohren, E., Simon, G.R., Swanson, S.J., Wood, D.E., Yang, S.C.: Non-small cell lung cancer. J Nat. Comp. Cancer Netw. 8(7), 740–801 (2010)
20. Ettinger, D.S., Akerley, W., Borghaein, H., Chnag, A.C., Cheney, R.T., Chirieac, L.R., D’Amico, T.A., Demmy, T.L., Govindan, R., Grannis, F.W., Jr., Grant, S.C., Horn, L.: Non-Small Cell Lung Cancer—NCCL Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network (NCCN). (2013)
21. Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie e.V. (DGHO): Onkopedia–Leitinien—Lungenkarzinom, nicht-kleinzellig (NSCLC). Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen (2012)
22. Peters, S., Adjei, A., Gridelli, C., Reck, M., Kerr, K., Felip, E.: Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 23(suppl 7), vii56–vii64 (2012)
23. Blinman, P., Alam, M., Duric, V., McLachlan, S.A., Stockler, M.R.: Patients’ preferences for chemotherapy in non-small-cell lung cancer: a systematic review. Lung Cancer 69(2), 141–147 (2010). doi:10.1016/j.lungcan.2010.05.001
24. Silvestri, G., Pritchard, R., Welch, H.G.: Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 317(7161), 771–775 (1998). doi:10.1136/bmj.317.7161.771
25. Brundage, M.D., Davidson, J.R., Mackillop, W.J.: Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 15(1), 330–340 (1997)
26. Dorman, S., Hayes, J., Pease, N.: What do patients with brain metastases from non-small cell lung cancer want from their treatment? Palliat Med 23(7), 594–600 (2009). doi:10.1177/0269216309105787
27. Dubey, S., Brown, R.L., Esmond, S.L., Bowers, B.J., Healy, J.M., Schiller, J.H.: Patient preferences in choosing chemotherapy regimens for advanced non-small cell lung cancer. J Support Oncol 3(2), 149–154 (2005)
28. ®). http://www.cancer.gov/cancertopics/pdq/treatment/non-small-cell-lung/Patient/page4 (2012)
29. Heitmann, C., Thomas, M.: Präoperative trimodale Induktionstherapie beim lokal weit fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom. Münster, Westfälische Wilhelms-Universität Münster, Diss., 2011 (2011)
30. American Cancer Society: Lung Cancer (Non-Small Cell) http://www.cancer.org/Cancer/LungCancer-Non-SmallCell/DetailedGuide/non-small-cell-lung-cancer-what-is-cancer (2012)
31. Lancaster, K.J.: A new approach to consumer theory. J Political Econ 74(2), 132–157 (1966)
32. McFadden, D.: Conditional logit analysis of qualitative choice behavior. In: Zarembka, P. (ed.) Frontiers in econometrics, pp. 105–142. Acedemic Press, New York (1974)
33. Ben-Akiva, M.E., Lerman, S.R.: Discrete choice analysis: theory and application to travel demand. MIT Press series in transportation studies. MIT Press, Cambridge, Mass. [u.a.] (1985)
34. Hensher, D.A., Rose, J.M., Greene, W.H.: Applied choice analysis: a primer. Cambridge University Press, Cambridge (2005)
35. Johnson, F.R.: Why not ask?: measuring patient preferences for healthcare decision making. Patient 1(4), 245–248 (2008)
36. Lancsar, E., Louviere, J.: Conducting discrete choice experiments to inform healthcare decision making: a user’s guide. Pharmacoeconomics 26(8), 661–678 (2008)
37. Ryan, M., Gerard, K., Amaya-Amaya, M.: Using discrete choice experiments to value health and health care. The economics of non-market goods and resources. Springer, Dordrecht (2008)
38. de Bekker-Grob, E.W., Ryan, M., Gerard, K.: Discrete choice experiments in health economics: a review of the literature. Health Econ. 21(2), 145–172 (2012). doi:10.1002/hec.1697
39. Bridges, J., Hauber, B., Marshall, D., Lloyd, A., Prosser, L.A., Regier, D.A., Johnson, R.F., Mauskopf, J.: Conjoint Analysis Use in Health Studies—A Checklist: A Report of the ISPOR Conjoint Analysis in Health Good Research Practices Task Force. ISPOR TF Report (2011)
40. Kornmeier, M.: Wissenschaftstheorie und wissenschaftliches Arbeiten: eine Einführung für Wirtschaftswissenschaftler. Physica-Verlag Heidelberg (2007)
41. Helm, R., Steiner, M.: Präferenzmessung: Methodengestützte Entwicklung zielgruppenspezifischer Produktinnovationen. W. Kohlhammer Verlag, Stuttgart (2008)
42. US Department of Health and Human Services, Office of Human Research Protection: Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events (2007)
43. Reed Johnson, F., Lancsar, E., Marshall, D., Kilambi, V., Mühlbacher, A., Regier, D.A., Bresnahan, B.W., Kanninen, B., Bridges, J.F.: Constructing experimental designs for discrete-choice experiments: report of the ISPOR conjoint analysis experimental design good research practices task force. Value Health 16(1), 3–13 (2013)
44. Orme, B.K.: Sample size issues for conjoint analysis. In: getting started with conjoint analysis, pp. 57–66. Research Publishers LLC, Madison (2010)
45. Rabe-Hesketh, S., Skrondal, A., Pickles, A.: GLLAMM Manual. Division of Biostatistics Working Paper Series, U.C. Berkeley (2004)
46. Rabe-Hesketh, S., Skrondal, A., Pickles, A.: Maximum likelihood estimation of limited and discrete dependent variable models with nested random effects. J Econom 128(2), 301–323 (2005)
47. Bridges, J.F.P., Mohamed, A.F., Finnern, H.W., Woehl, A., Hauber, A.B.: Patients’ preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer 77(1), 224–231 (2012)
48. Petrelli, F., Borgonovo, K., Cabiddu, M., Veronica, L., Barni, S.: Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials. Lung Cancer 78(1), 8–15 (2012)
49. Brundage, M., Feldman-Stewart, D., Cosby, R., Gregg, R., Dixon, P., Youssef, Y., Mackillop, W.: Cancer patients’ attitudes toward treatment options for advanced non-small cell lung cancer: implications for patient education and decision support. Patient Educ Couns 45(2), 149–157 (2001)
50. Hirose, T., Horichi, N., Ohmori, T., Kusumoto, S., Sugiyama, T., Shirai, T., Ozawa, T., Ohnishi, T., Adachi, M.: Patients preferences in chemotherapy for advanced non-small-cell lung cancer. Intern Med 44(2), 107–113 (2005). JST.JSTAGE/internalmedicine/44.107 [pii]
51. Hirose, T., Yamaoka, T., Ohnishi, T., Sugiyama, T., Kusumoto, S., Shirai, T., Okuda, K., Ohmori, T., Adachi, M.: Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer. Psycho-Oncology 18(5), 483–489 (2009)